We felt the urgency to launch the EU2Cure Consortium to support research and find a cure for the human immunodeficiency virus (HIV) infection through intensified collaboration within Europe. This consortium is open to stakeholders on cure in Europe from academia and the community to connect. The aim of this consortium is to intensify the research collaboration amongst European HIV cure groups and the community and facilitate interactions with other academic and community cure consortia, private parties, and policy makers. Our main aim is to create a European research agenda, data sharing, and development of best practice for clinical and translational science to achieve breakthroughs with clinically feasible HIV cure strategies. This consortium should also enable setting up collaborative studies accessible to a broader group of people living with HIV. Besides reservoir studies, we have identified three overlapping scientific interests in the consortium that provide a starting point for further research within a European network: developing “shock and kill” cure strategies, defining HIV cure biomarkers, and connecting cure cohorts. This strategy should aid stakeholders to sustain progress in HIV cure research regardless of coincidental global health or political crises.

我们感到迫切需要启动 EU2Cure 联盟，以支持研究，并通过在欧洲加强合作来寻找治疗人类免疫缺陷病毒 (HIV) 感染的方法。该联盟向来自学术界和社区的欧洲治愈方面的利益相关者开放。该联盟的目的是加强欧洲 HIV 治愈团体和社区之间的研究合作，并促进与其他学术和社区治愈联盟、私人团体和政策制定者的互动。我们的主要目标是为临床和转化科学制定欧洲研究议程、数据共享和开发最佳实践，以通过临床上可行的 HIV 治愈策略取得突破。该联盟还应该能够建立更广泛的艾滋病毒感染者群体可以进行的合作研究。除了储层研究之外，我们还在该联盟中确定了三个重叠的科学兴趣，为欧洲网络内的进一步研究提供了起点：制定“休克和杀死”治愈策略、定义 HIV 治愈生物标志物以及连接治愈队列。该策略应帮助利益相关者保持 HIV 治愈研究的进展，无论是否发生巧合的全球健康或政治危机。